288 related articles for article (PubMed ID: 25082556)
21. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.
Kendler DL; Palacios S; Cox DA; Stock J; Alam J; Dowsett SA; Zanchetta J
Osteoporos Int; 2012 Mar; 23(3):1091-101. PubMed ID: 21374068
[TBL] [Abstract][Full Text] [Related]
22. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
[TBL] [Abstract][Full Text] [Related]
23. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
24. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.
Ebina K; Hirao M; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Okamura G; Etani Y; Takami K; Goshima A; Nakata K
Bone; 2020 Nov; 140():115574. PubMed ID: 32777516
[TBL] [Abstract][Full Text] [Related]
25. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
27. Short-term daily teriparatide in patients with rheumatoid arthritis.
Kaneko T; Okamura K; Yonemoto Y; Okura C; Suto T; Tachibana M; Tamura Y; Inoue M; Chikuda H
Mod Rheumatol; 2018 May; 28(3):468-473. PubMed ID: 28805099
[TBL] [Abstract][Full Text] [Related]
28. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis GN; Efstathiadou Z; Kita M; Avramidis A
Int J Clin Pract; 2008 Jun; 62(6):919-24. PubMed ID: 18422590
[TBL] [Abstract][Full Text] [Related]
29. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
30. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.
Miyauchi A; Matsumoto T; Shigeta H; Tsujimoto M; Thiebaud D; Nakamura T
J Bone Miner Metab; 2008; 26(6):624-34. PubMed ID: 18979163
[TBL] [Abstract][Full Text] [Related]
31. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
32. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results.
Silverman S; Miller P; Sebba A; Weitz M; Wan X; Alam J; Masica D; Taylor KA; Ruff VA; Krohn K
Osteoporos Int; 2013 Aug; 24(8):2309-17. PubMed ID: 23404615
[TBL] [Abstract][Full Text] [Related]
33. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
34. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
35. Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis.
Gonnelli S; Martini G; Caffarelli C; Salvadori S; Cadirni A; Montagnani A; Nuti R
Osteoporos Int; 2006 Oct; 17(10):1524-31. PubMed ID: 16767526
[TBL] [Abstract][Full Text] [Related]
36. Association between P1NP and bone strength in postmenopausal women treated with teriparatide.
Chen FP; Fu TS; Lin YC; Sung CM; Huang MH; Lin YJ
Taiwan J Obstet Gynecol; 2022 Jan; 61(1):91-95. PubMed ID: 35181054
[TBL] [Abstract][Full Text] [Related]
37. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
[TBL] [Abstract][Full Text] [Related]
38. The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial.
Jepsen DB; Ryg J; Hansen S; Jørgensen NR; Gram J; Masud T
Osteoporos Int; 2019 Sep; 30(9):1827-1836. PubMed ID: 31309239
[TBL] [Abstract][Full Text] [Related]
39. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women.
Cosman F; Lane NE; Bolognese MA; Zanchetta JR; Garcia-Hernandez PA; Sees K; Matriano JA; Gaumer K; Daddona PE
J Clin Endocrinol Metab; 2010 Jan; 95(1):151-8. PubMed ID: 19858319
[TBL] [Abstract][Full Text] [Related]
40. ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY.
Gopalaswamy V; Dhibar DP; Gupta V; Arya AK; Khandelwal N; Bhansali A; Garg SK; Agarwal N; Rao SD; Bhadada SK
Endocr Pract; 2017 Jun; 23(6):657-661. PubMed ID: 28225309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
